Skip to main content
SpringerLink
Log in

New Treatments for Myocardial Fibrosis

  • Editorial Board
  • Published:
Cardiovascular Drugs and Therapy Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertension 1998;16:1031–1041.

    Google Scholar 

  2. Bishop JE, Greenbaum R, Gibson DG, Yacoub M, Laurent GJ. Enhanced deposition of predominantly type I collagen in myocardial disease. J Mol Cell Cardiol 1990;22:1157–1165.

    Google Scholar 

  3. Wei S, Chow LTC, Shum OL, Qin L, Sanderson JE. J Cardiac Failure 1999;5:117–126.

    Google Scholar 

  4. Weber KT. Targeting pathological remodeling. Concepts of cardioprotection and reparation. Circulation 2000;102:1342–1345.

    Google Scholar 

  5. Bishop JE, Lindahl G. Regulation of cardiovascular collagen synthesis by mechanical load. Cardiovasc Res 1999;42:27–44.

    Google Scholar 

  6. Mann DL, Spinnale FG. Activation of matrix metalloproteinases in the failing human heart: Breaking the tie that binds. Circulation 1998;98:1699–1702.

    Google Scholar 

  7. Sanderson JE, Lai KB, Shum IOL, Wei S, Chow LTC. Transforming growth factor-? expression in dilated cardiomyopathy. Heart 2001;86:701–702.

    Google Scholar 

  8. Silvestre JR, Heymes C, Oubenaissa A, et al. Activation of cardiac aldosterone production in rat myocardial infarction: Effect of angiotensin II receptor blockade and role in cardiac fibrosis. Circulation 1999;99:2694–2701.

    Google Scholar 

  9. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation 2000;102:1388–1393.

    Google Scholar 

  10. Wei S, Chow LTC, Sanderson JE. Effect of carvedilol in comparison with metoprolol on myocardial collagen postinfarction. J Am Coll Cardiol 2000;36:276–281.

    Google Scholar 

  11. Sia YT, Parker TG, Tsoporis JN, Liu P, Adam A, Rouleau JL. Long-term effects of carvedilol on left ventricular function, remodeling, and expression of cardiac cytokines after large myocardial infarction in the rat. J Cardiovasc Pharm 2002;39:73–87.

    Google Scholar 

  12. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium: fibrosis and rennin-angiotensin-aldosterone system. Circulation 1991;83:1849–1865.

    Google Scholar 

  13. Sanderson JE, Cockram CS, Yu CM, Campbell SE, Weber KT. Myocardial fibrosis and hyperaldosteronism. Eur Heart J 1996;17:1761–1762.

    Google Scholar 

  14. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 1999;341:709–717.

    Google Scholar 

  15. Cittadini A, Casaburi C, Monti MG, et al. Effects of canrenone on myocardial reactive fibrosis in a rat model of postinfarction heart failure. Cardiovasc Drugs Ther 2002;16(3):195–202.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Cardiology, Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, People's Republic of China

    John E. Sanderson

Authors
  1. John E. Sanderson
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Sanderson, J.E. New Treatments for Myocardial Fibrosis. Cardiovasc Drugs Ther 16, 181–182 (2002). https://doi.org/10.1023/A:1020636002954

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020636002954

Search

Navigation